InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.115 -0.025 (-17.86%)+
Announcement
Release
14 May 2026 9:37AM
Price at Release
$0.140
Full Release
download
Summary
Lumos Diagnostics Holdings Limited, a leader in rapid point-of-care diagnostic technologies, announced the successful completion of milestone #7 for the enrolment of 250 patients in the BARDA-funded FebriDx® paediatric clinical study. This milestone triggers a US$670,000 payment, accumulating a total of US$2,590,000 in milestone payments. The study aims to expand the use of FebriDx®, a diagnostic tool for differentiating bacterial from non-bacterial acute respiratory infections, to include patients aged 2-64 years. The study, expected to last 12 months, will lead to a formal submission to the FDA for further approvals. Lumos Diagnostics is focused on enhancing the clinical use of FebriDx® and supporting informed clinical decision-making to reduce unnecessary antibiotic prescriptions.
Key Points
  • Milestone #7 involves 250 patient enrolment
  • Triggers US$670,000 payment, totaling US$2,590,000
  • BARDA committed US$6,198,459 for all milestones
  • FebriDx® differentiates bacterial from non-bacterial infections
  • Study targets age group 2-64 years
  • Formal FDA submission expected post-study
  • Study duration is approximately 12 months
  • Lumos aims to expand FebriDx® in US market
  • Supports informed clinical decision-making
  • Reduces unnecessary antibiotic prescriptions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.